Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
- 1 February 2018
- journal article
- review article
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 27 (2) , 381-390
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Functional Outcome Measures in Contemporary Stroke TrialsInternational Journal of Stroke, 2009
- Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational studyThe Lancet, 2007
- The Val34Leu Polymorphism in the A Subunit of Coagulation Factor XIII Contributes to the Large Normal Range in Activity and Demonstrates That the Activation Peptide Plays a Role in Catalytic ActivityBlood, 1998
- Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)The Lancet, 1998
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Intracarotid Recombinant Tissue Plasminogen Activator in Acute Carotid Artery Territory Stroke1995
- Intravenous Tissue Plasminogen Activator Ameliorates the Outcome of Hyperacute Embolic StrokeCerebrovascular Diseases, 1993
- Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group.Stroke, 1993
- Plasma fibrinogen and its correlates in Japanese and US population samples.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
- Antigens of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor 1: Correlates in Nonsmoking Japanese and Caucasian Men and WomenThrombosis and Haemostasis, 1993